<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933370</url>
  </required_header>
  <id_info>
    <org_study_id>REB21-0692</org_study_id>
    <nct_id>NCT04933370</nct_id>
  </id_info>
  <brief_title>Neuromodulation Parameter Efficacy</brief_title>
  <official_title>Evaluating the Efficacy of Different Stimulation Paradigms in Neuromodulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services, Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alberta Health Services, Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy of neuromodulation using various&#xD;
      stimulation paradigms in the treatment of several disorders including chronic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Different stimulation parameters will be tried in a blinded fashion to compare efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline pain measures</measure>
    <time_frame>6 months</time_frame>
    <description>Pain outcomes measured using visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of stimulation on quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>As measured using EQ-5D-3L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Industry standard stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Industry standard stimulation settings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Experimental stimulation settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stimulation parameters</intervention_name>
    <description>Different device stimulation parameters</description>
    <arm_group_label>Experimental stimulation</arm_group_label>
    <arm_group_label>Industry standard stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are candidates for, and have been consented for, implantation of a&#xD;
             neuromodulation device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alberta Health Services, Calgary</investigator_affiliation>
    <investigator_full_name>Fady Girgis</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

